No Data
Fujian Cosunter Pharmaceutical (300436.SZ): The preliminary results of Phase II clinical trial research on GST-HG141 will not have a significant impact on the company's performance in the short term.
On August 14th, Gelonhui announced abnormal volatility in the stocks of Fujian Cosunter Pharmaceutical (300436.SZ). On August 12th, 2024, the company disclosed an announcement regarding the preliminary results of phase II clinical trial research on innovative drugs for hepatitis B treatment GST-HG141, which has achieved its preset goals. The company noticed that some media, stock forums, public accounts, and other platforms have reposted and discussed relevant matters, which has attracted high market attention. The unblinding results of the phase II study of GST-HG141 are only preliminary statistical analysis results. The complete safety and pharmacological results will be determined by the final clinical summary report, and further work is still required.
Even After Rising 20% This Past Week, Fujian Cosunter Pharmaceutical (SZSE:300436) Shareholders Are Still Down 50% Over the Past Three Years
Fujian Cosunter Pharmaceutical (300436.SZ): Plans to complete the construction project of integrated production base for active pharmaceutical ingredients and will permanently supplement working capital with the remaining funds raised.
On July 30th, Gelonhui reported that Fujian Cosunter Pharmaceutical (300436.SZ) held the second meeting of the fifth session of the Board of Directors and the second meeting of the fifth session of the Supervisory Committee on July 30, 2024. They reviewed and passed the Proposal on Part of the Fundraising Projects for Completion and the Permanent Supplementation of Working Capital with the Surplus Raised Funds. The investment project of the active pharmaceutical ingredient and drug preparation integrated production base construction project from the fundraising project for the issuance of A-shares of the company to specific objects on the Growth Enterprise Market in 2020 has reached the intended usable state and meets the completion conditions. The company plans to use the surplus funds of the project to permanently supplement the working capital and authorizes the management of the company at the same time.
Guangshengtang (300436.SZ) reported 2023 annual results, with a net loss of 349 million yuan, an increase in year-on-year losses
Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...
More Unpleasant Surprises Could Be In Store For Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares After Tumbling 28%
Guangshengtang (300436.SZ): Obtaining a patent certificate or authorization notice for a new drug under development
Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development. The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel, and have been exhausted up to now
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%No Data
